CareDx slides as rally cools with no fresh company catalyst evident

CareDx (CDNA) is down 7.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely explanation is a sharp pullback after a very strong recent run, rather than a new fundamental setback. No fresh negative operating update was easy to confirm, so this could be because traders locked in gains after the stock reached new highs and after recent insider Form 4 filings hit the tape.

Details:

CDNA had rallied strongly into this session, closing at $69.85 on October 5 after gaining about 28% over the prior two weeks, which set up the stock for profit-taking.

CareDx’s most recent major business update remained constructive: second-quarter 2026 revenue rose to about $132 million and the company raised full-year 2026 revenue and adjusted EBITDA guidance.

CareDx also benefited recently from finalized Medicare coverage terms for its transplant molecular testing menu, which had removed a reimbursement overhang and likely contributed to the earlier surge.

Several insider Form 4 filings were disclosed on October 5, including tax-withholding related dispositions tied to equity awards for senior executives, which may have added to short-term selling pressure even if the transactions were not large enough on their own to explain the full move.

Sources:

SEC, CareDx Investor Relations, Stock Analysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CDNA Insider Trading Activity

$CDNA insiders have traded $CDNA stock on the open market 19 times in the past 6 months. Of those trades, 0 have been purchases and 19 have been sales.

Here’s a breakdown of recent trading of $CDNA stock by insiders over the last 6 months:

JOHN WALTER JR HANNA (President and CEO) has made 0 purchases and 8 sales selling 212,798 shares for an estimated $6,914,891.
MICHAEL GOLDBERG sold 44,700 shares for an estimated $2,103,497
HANNAH VALANTINE has made 0 purchases and 3 sales selling 40,882 shares for an estimated $1,319,971.
GEORGE BICKERSTAFF sold 20,000 shares for an estimated $925,699
CHRISTINE COURNOYER sold 16,000 shares for an estimated $750,972
ARTHUR A TORRES has made 0 purchases and 2 sales selling 10,570 shares for an estimated $214,675.
JEFFREY ADAM NOVACK (Secretary and General Counsel) has made 0 purchases and 3 sales selling 5,376 shares for an estimated $179,930.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive CDNA Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$CDNA Hedge Fund Activity

We have seen 116 institutional investors add shares of $CDNA stock to their portfolio, and 79 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BAMCO INC /NY/ removed 1,399,083 shares (-41.9%) from their portfolio in Q2 2026, for an estimated $39,873,865
DIVISADERO STREET CAPITAL MANAGEMENT, LP added 700,938 shares (+inf%) to their portfolio in Q2 2026, for an estimated $19,976,733
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 538,125 shares (+inf%) to their portfolio in Q2 2026, for an estimated $15,336,562
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 372,111 shares (+inf%) to their portfolio in Q2 2026, for an estimated $10,605,163
QUBE RESEARCH & TECHNOLOGIES LTD added 369,837 shares (+inf%) to their portfolio in Q2 2026, for an estimated $10,540,354
BRAIDWELL LP removed 364,618 shares (-23.0%) from their portfolio in Q2 2026, for an estimated $10,391,613
MORGAN STANLEY added 348,950 shares (+82.0%) to their portfolio in Q2 2026, for an estimated $9,945,075

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$CDNA Government Contracts

We have seen $7,339,543 of award payments to $CDNA over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

ALLOMAP AND ALLOSURE POST HEART TRANSPLANT REJECTION SURVEILLANCE TESTS SERVICES: $429,258
ALLOSURE IN-HOME PATIENT TESTING: $142,037
ALLOSURE KIDNEY TEST: $48,292

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.